VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESO

Contact Us

Products

• Core Product
• API
• Formulation
• Quality Assurance

Science

• R&D
• Solutions

About Us

• Who are we
• Our history
• Main production base
• Governance and Leadership